Welcome to our dedicated page for Petvivo Hldgs SEC filings (Ticker: PETV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding the science behind PetVivo Holdings Inc.’s Spryng with OsteoCushion Technology can turn a single 10-K into an all-night read. R&D expenses, patent claims on extracellular-matrix biomaterials, and veterinary regulatory updates are scattered across hundreds of pages—making it tough to pinpoint what really moves PETV’s valuation.
Stock Titan’s AI-powered engine translates that complexity into plain language. Whether you need the PetVivo quarterly earnings report 10-Q filing, an 8-K material events explained summary on a new distribution deal, or PetVivo insider trading Form 4 transactions in real time, the platform delivers concise highlights, red-flag alerts, and side-by-side trend charts. Our coverage spans every form—10-K annual report, proxy statement executive compensation details, and executive stock transactions Form 4—updated the moment PetVivo pushes data to EDGAR.
Here’s how professionals use it:
- Spot cash-burn trends and manufacturing scale-up costs without wading through accounting footnotes.
- Track PetVivo Form 4 insider transactions real-time to gauge management sentiment before material announcements.
- Compare quarter-over-quarter sales progress for Spryng using AI-generated tables drawn from each 10-Q.
- Understand PetVivo SEC documents with AI that flags new patent additions and regulatory milestones.
- Pull talking points from the PetVivo annual report 10-K simplified summary in minutes, not hours.
No more piecing together disclosures. Get every PetVivo SEC filing explained simply, refreshed instantly, and ready for action—so you can focus on making informed decisions, not flipping pages.
PetVivo Holdings (PETV) reported Q2 FY2026 results. Revenue was $303,284 versus $200,720 a year ago, driven mainly by sales to Vedco after prior distributor agreements were terminated. Gross profit was $220,058. The company recorded a net loss of $3,007,809 for the quarter and $5,318,846 for the six months.
Cash was $767,914 and stockholders’ equity $4,182,972 at September 30, 2025. Total liabilities fell to $1,075,297 from $5,119,947, reflecting the conversion of $1,850,000 in convertible notes plus interest into 3,669,806 shares and the elimination of derivative liabilities. Operating cash outflow was $3,828,209 for the six months, partly offset by $4,361,829 of financing inflows, including receipt of the remaining $4,400,000 under the $5,000,000 Series B Preferred subscription (10% annual dividend payable in stock).
The company added two licensing assets: VetStem PRP ($2,000,000 fee) and an AI software license ($800,000 paid in stock). Shares outstanding were 33,580,630 as of November 14, 2025. Management disclosed substantial doubt about the company’s ability to continue as a going concern.
PetVivo Holdings, Inc. (PETV) furnished an investor presentation as Exhibit 99.1 via an 8‑K. The Company states representatives may use this presentation at investor conferences and other forums, and it may also appear on the corporate website.
The information is provided under Regulation FD, Item 7.01, is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced. The exhibit is titled “PetVivo Holdings, Inc. Investor Presentation” and is dated November 2025.
A.L. Sarroff Fund, LLC filed Amendment No. 10 to Schedule 13G reporting beneficial ownership of 8,846,288 shares of PetVivo Holdings, Inc. common stock, representing 31.7% of the class. The filer reports sole voting and sole dispositive power over the same 8,846,288 shares, with no shared power.
The filing states reliance on Rule 13d-1(c) and certifies the securities were not acquired to change or influence control. It also discloses 4,780,008 warrants with specified future exercisability dates that are not included in the Schedule 13G ownership per Rule 13d-3(d)(1). As context, the issuer had 27,903,361 shares outstanding as of August 14, 2025, and the filer notes its holdings were 26.5% as of June 30, 2025.
PetVivo Holdings (PETV) expanded its Board to eight directors and appointed Josh Ruben, effective October 28, 2025. Ruben, age 39, was deemed “independent” under Exchange Act rules and will serve until the next annual meeting and until a successor is elected and qualified.
Ruben is Managing Director of Life Sciences at Trinity Capital and previously led Life Science Tools and Diagnostics coverage at RBC Capital Markets after nine years at Wells Fargo Securities. His compensation will align with the Company’s non-employee director program on a pro‑rated basis. He has no disclosed related-party transactions or family relationships with current directors or officers and has not yet been appointed to any committees.
PetVivo Holdings (PETV) reported an insider transaction on Form 4. Chief Financial Officer Garry Lowenthal received 75,000 shares of restricted common stock on 10/23/2025 at a reported price of $1.27 per share. The grant was issued to a corporation owned by him as compensation for past performance. After this grant, he beneficially owns 667,967 shares, held indirectly through the corporation.
PetVivo Holdings (PETV) reported an insider transaction on a Form 4. CEO and Director John Lai acquired 75,000 shares of common stock on 10/23/2025 at $1.27 per share. The filing states the shares were a grant of restricted common stock to a corporation he owns, as compensation for past performance by converting a past accrued bonus into common stock.
After the transaction, Lai beneficially owned 2,095,710 shares, held indirectly through the corporation.
PetVivo Holdings (PETV) reported an insider equity grant. Director Spencer Breithaupt acquired 12,500 shares of common stock on 10/10/2025 at $1.28 per share. The transaction reflects an annual Board compensation award of 50,000 restricted shares, vesting in four equal quarterly installments of 12,500 at the beginning of each quarter. Following the transaction, Breithaupt beneficially owns 60,187 shares, held directly.
PetVivo Holdings (PETV) reported an insider equity award. Director Diane Levitan acquired 12,500 shares of restricted common stock at $1.28 on 10/10/2025. The award is part of an aggregate annual grant of 50,000 shares for Board service, vesting in four equal installments of 12,500 at the beginning of each quarter.
Following this transaction, Levitan beneficially owns 56,489 shares, held directly.
PetVivo Holdings (PETV) director reported multiple stock grants. On 10/01/2025, the director acquired 14,935 shares of restricted common stock at $1.19 as compensation for prior consulting services. On 10/10/2025, additional restricted stock grants were recorded: 12,500 shares at $1.28 for quarterly Board service vesting, 50,000 shares at $1.28 tied to a warrant exercise with a $25,000 payment to the company, and 100,000 shares at $1.28 tied to a warrant exercise with a $50,000 payment to the company. Following these transactions, beneficial ownership stood at 311,807 shares, held directly.
PetVivo Holdings (PETV) reported a Form 4 for director Robert Rudelius. On 10/10/2025, he acquired 12,500 shares of common stock at $1.28 as part of an annual 50,000 restricted-share board compensation grant that vests in four equal quarterly installments. Following the transaction, he beneficially owned 314,369 shares directly and 21,000 shares indirectly via a corporation.
FAQ
What is the current stock price of Petvivo Hldgs (PETV)?
What is the market cap of Petvivo Hldgs (PETV)?
